Study aim: To determine the effect of curcumin on fatigue, sleep quality, and appetite in women with breast cancer undergoing chemotherapy Design: Clinical Trial, by using block randomization, the Patients enter in intervention, or control group, A pilot study including10 patients from each group, will determine the size of the sample, Parallel groups, triple-blind Settings and conduct: This study is a triple-blind clinical trial conducted at Kowsar Hospital in Semnan. Participants/Inclusion and exclusion criteria: Inclusion criteria: Breast cancer diagnosis at least six months or more, Women undergoing chemotherapy, Women over 18 years of age, Sleep quality higher than 5 on the Pittsburgh scale, Informed consent to participate in the study. Exclusion criteria:Discontinuation of chemotherapy, Intolerance to curcumin or history of sensitivity to curcumin, Failure to fully participate in the one-month period, Voluntary withdrawal, History of mental disorders, Unstable medical conditions or concomitant diseases, Hospitalization during the study, History of cancer-related surgery, Metastasis to other sites, Death during the study. Intervention groups: The intervention group received 500 mg of Curcumin Longa tablets once a day with lunch for one month, in addition to their routine regimen. The control group received a placebo tablet once a day with lunch for one month, also in addition to their routine regimen. Main outcome variables: Sleep quality, fatigue, and appetite